-
Drugs: Bimalizumab in the treatment of psoriasis
Time of Update: 2021-11-03
Research evidence shows that the interleukin (IL)-23/IL-17 immune pathway is a key factor in the inflammation of psoriasis, which supports the development of several new and effective targeted therapies for the treatment of psoriasis, including IL- 17A ixekizumab and seckinumab, brodalab for the IL-17 receptor subunit, and risankizumab, guselkumab, and tildrakizumab for IL-23 .
-
Lancet Rheumatology: Efficacy of Guselkumab on the central axis of patients with active psoriatic arthritis and sacroiliitis
Time of Update: 2021-11-03
Efficacy assessments include the Basal Ankylosing Spondylitis Disease Activity Index (BASDAI) score, modified BASDAI (mBASDAI ; excluding peripheral joint pain ) , spinal pain, and ankylosing spondylitis disease activity score (ASDAS) least squares mean changes, 95 CI% , and BASDAI score (BASDAI50) improved by at least 50% and reached inactive disease ASDAS reaction (rates <1.
-
Clin Rev Allergy Immunol: Systemic Lupus Erythematosus and Pregnancy: A Portuguese Case Control Study
Time of Update: 2021-11-03
The purpose of the study was to evaluate the maternal and infant outcomes of a group of Portuguese patients with systemic lupus erythematosus and compare them with a group of healthy pregnant women .
-
Nature Immunology, Zhao Yang and others found that blind mole rats use "junk DNA" to fight cancer
Time of Update: 2021-11-03
On September 23, 2021, the team of Vera Gorbunova and Andrei Seluanov of the University of Rochester in the United States published a research paper entitled Transposon-triggered innate immune response confers cancer resistance to the blind mole rat in Nature Immunology, which first revealed the anti-cancer effect of blind mole rat Mechanism .
-
Lancet rheumatology: Treatment gradual reduction and discontinuation of patients with rheumatoid arthritis in stable remission (RETRO): a multicenter, randomized, controlled, open-label phase 3 trial
Time of Update: 2021-11-03
Sustained remission of rheumatoid arthritis (RETRO) study examined the reduction and disabling disease-modifying antirheumatic drugs stable remission in patients with rheumatoid arthritis (DMARD) , to test whether can not accept DMARD maintaining remission in the case of treatment .
-
Rheumatology: Risks, predictors and prognosis of amyloidosis in patients with ankylosing spondylitis
Time of Update: 2021-11-03
Rheumatology (Oxford) 2021 Aug 09 Kridin M, Kridin K, Cohen A , The risk, predictors, and outcomes of amyloidosis in ankylosing spondylitis: a longitudinal population-based cohort study.
, The risk, predictors, and outcomes of amyloidosis in ankylosing spondylitis: a longitudinal population-based cohort study.
-
ARD: Inactivated vaccines may not provide adequate protection for immunosuppressed patients with rheumatism
Time of Update: 2021-11-03
Researchers at approximately 1500 name own immune rheumatic diseases ( AIRD patients) were followed to evaluate COVID-19 queue immunogenicity of the vaccine, it is determined the 475 patients had completed two vaccination .
In order to check the serum neutralization potential, chosen age, gender and disease matched 80 Ming BBV152 and 85 Ming AZD1222 vaccinated .
-
Front Immunol: Clinical experience on the efficacy and safety of proteasome inhibitor bortezomib in the treatment of severe systemic lupus erythematosus
Time of Update: 2021-11-03
Although advances in treatment strategies have improved the prognosis, patients with systemic lupus erythematosus (SLE) still face some challenges .
This article reports the clinical experience of the effectiveness and safety of all patients receiving phenytoin in the treatment of systemic lupus erythematosus in Sweden from 2014 to 2020 .
-
(Less than 500 words) Ann Rheum Dis: The relationship between two doses of COVID-19 vaccine and arthritis in patients with rheumatoid arthritis
Time of Update: 2021-11-03
COVID-19Researchers identified rheumatoid arthritis (RA) patients from population-based electronic medical records and divided them into BNT162b2 (mRNA vaccine), CoronaVac (inactivated virus vaccine) and non-vaccinated groups .
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong .
-
Rheumatology: The effect of fegotinib on the structural damage of sacroiliac joint MRI at 12 weeks in patients with active ankylosing spondylitis (Tortuga test)
Time of Update: 2021-11-03
Rheumatology (Oxford) 2021 Aug 05Maksymowych WP, Østergaard M, Landewé R , Impact of filgotinib on sacroiliac joint MRI structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial) .
-
Front Med: A Randomized Controlled Clinical Trial Study on the Treatment of Primary Sjogren’s Syndrome with Traditional Chinese Medicine
Time of Update: 2021-11-02
Although the ESSPRI score does not show the efficacy of traditional Chinese medicine in the treatment of Sjogren’s syndrome, there are other shortcomings, but the PSQI score shows that the formula can prolong the patient’s sleep time , and can also reduce the serum IgG level and the patient’s blood pressure .
-
Guide Interpretation of the Asia-Pacific Lupus Erythematosus Guide, these 26 key points have been drawn!
Time of Update: 2021-11-02
A meta-analysis of five small controlled trials from Asia showed that tacrolimus was superior to intravenous pulsed cyclophosphamide in the induction treatment of lupus nephritis, and another RCT showed that tacrolimus induced a complete renal response at 24 weeks Mycophenolate mofetilThose that do not respond well to the standard regimen can be mycophenolate mofetil/tacrolimus combination or rituximab .
-
Ann Rheum Dis: Heredity of idiopathic inflammatory myopathy
Time of Update: 2021-11-02
IIM has a family genetic component, there is a risk of family aggregation in first-degree relatives, and its heritability is about 20% .
IIM has a family genetic component, and there is a family gathering risk in first-degree relatives, and its heritability is about 20% .
-
Annals of the Rheumatic Diseases: B-cell removal treatment of proliferative lupus nephritis with obituzumab: a randomized, double-blind, placebo-controlled trial
Time of Update: 2021-11-02
Conclusion : As of 104 weeks, the combination of orbituzumab with standard therapy improves renal response in patients with LN compared with standard therapy alone .
1136/annrheumdis-2021-220920Furie RA, Aroca G, Cascino MD , et al B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
-
JAMA: The effect of costimulation blockade of abatacept on patients with moderate to severe plaque psoriasis after discontinuation of Uselumumab PAUSE randomized clinical trial
Time of Update: 2021-11-02
experimental design:Treatment of psoriasis with abatacept and usnumab: The Efficacy Study (PAUSE), a parallel-designed, double-blind, placebo-controlled randomized clinical trial conducted at 10 locations in the United States and Canada .
-
Ann Rheum Dis: Efficacy and safety of tiralizumab in the treatment of active psoriatic arthritis-results of a randomized, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
Time of Update: 2021-11-02
Recently, a randomized trial published in Ann Rheum Dis evaluated the efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tiralizumab in patients with psoriatic arthritis (PsA) .
, Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
-
J Immunother Cancer: Safety and effectiveness of immune checkpoint inhibitors in patients with previous psoriasis
Time of Update: 2021-11-02
Psoriasis vulgaris is a common, immune-mediated disease, and the results of ICI treatment of patients with psoriasis have not been well described .
Psoriasis vulgaris is a common, immune-mediated disease, and the results of ICI treatment of patients with psoriasis have not been well described .
-
Vitamin D can prevent rheumatism and immune diseases!
Time of Update: 2021-11-02
Active vitamin D combined with specific intracellular VDR can not only regulate bone calcium and phosphorus metabolism and improve osteoporosis , but also, as a hormone-like substance, can inhibit inflammatory cytokines such as interleukins through dendritic cells and T and B lymphocytes The synthesis of (IL)-17, interferon-γ, etc.
-
The US FDA approves Cyltezo (adalimumab-adbm) as the first biosimilar that is interchangeable with Humira
Time of Update: 2021-11-02
The additional studies showed that Cyltezo with Humira equivalent pharmacokinetics between the treatment group and converting the continuous treatment group, efficacy, immunological no significant differences in immunogenicity and safety , the results have been published in the American Academy of Dermatology Society meeting in 2021 .
-
Science: Reveal how cytotoxic T cells are reloaded with weapons and carry out multiple "kills"
Time of Update: 2021-11-01
The relevant research results were published in the Science Journal on October 15, 2021, with the title of the paper "Mitochondrial translation is required for sustained killing by cytotoxic T cells" .
